173 related articles for article (PubMed ID: 38682215)
1. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
[TBL] [Abstract][Full Text] [Related]
2. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Hubbard D; Hacksell U; McFarland K
Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
[TBL] [Abstract][Full Text] [Related]
4. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
8. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
9. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interventions for psychosis in Parkinson's disease patients.
Friedman JH
Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
[TBL] [Abstract][Full Text] [Related]
13. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Samudra N; Patel N; Womack KB; Khemani P; Chitnis S
Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568
[TBL] [Abstract][Full Text] [Related]
14. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Isaacson SH; Citrome L
Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psychosis in Parkinson's disease: safety considerations.
Fernandez HH; Trieschmann ME; Friedman JH
Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
[TBL] [Abstract][Full Text] [Related]
17. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
Duits JH; Ongering MS; Martens HJM; Schulte PFJ
Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
19. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Panchal SC; Ondo WG
Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
[TBL] [Abstract][Full Text] [Related]
20. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
